HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis.

Abstract
A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.
AuthorsAttapon Cheepsattayakorn, Ruangrong Cheepsattayakorn
JournalRecent patents on anti-infective drug discovery (Recent Pat Antiinfect Drug Discov) Vol. 7 Issue 2 Pg. 141-56 (Aug 2012) ISSN: 2212-4071 [Electronic] Netherlands
PMID22670838 (Publication Type: Journal Article, Review)
Chemical References
  • Antitubercular Agents
Topics
  • Animals
  • Antitubercular Agents (pharmacology, therapeutic use)
  • Extensively Drug-Resistant Tuberculosis (drug therapy)
  • Humans
  • Mycobacterium tuberculosis (drug effects)
  • Patents as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: